SCHEMBL4070595

SCHEMBL4070595

CC(C(=O)O)c1cccc(O)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2B P18089 2/20 0.47
ADRB1 P08588 1/20 0.47
ADRA2A P08913 1/20 0.47
ADRB3 P13945 1/20 0.47
ADRA2C P18825 1/20 0.47
PTGS2 P35354 8/20 0.45
PTGS1 P23219 8/20 0.45
CXCL8 P10145 1/20 0.43
GABRA1 P14867 2/20 0.41
GABRB2 P47870 2/20 0.41
AKR1C3 P42330 2/20 0.40
AKR1C2 P52895 2/20 0.40
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MMP12 P39900 1/20 0.40
MMP13 P45452 1/20 0.40
MMP14 P50281 1/20 0.40
MMP16 P51512 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27842026 0.87 ADRB1 (0.49) ADRA2BADRB1ADRA2AADRB3ADRA2C
SCHEMBL6491103 0.85 CES2 (0.51) ADRA2BPTGS2PTGS1CXCL8AKR1C3
SCHEMBL490576 0.81 PTGS2 (0.47) PTGS2PTGS1CXCL8GABRA1GABRB2
SCHEMBL7102472 0.81 PTGS2 (0.47) PTGS2PTGS1CXCL8GABRA1GABRB2
SCHEMBL153695 0.80 PTGS2 (0.59) PTGS2PTGS1CXCL8GABRA1GABRB2
SCHEMBL29237654 0.80 PTGS2 (0.44) ADRA2BPTGS2PTGS1CXCL8AKR1C3
SCHEMBL1679090 0.80 CXCL8 (0.56) PTGS2PTGS1CXCL8AKR1C3AKR1C2
SCHEMBL10687309 0.80 PTGS2 (0.44) ADRA2BPTGS2PTGS1CXCL8AKR1C3
SCHEMBL30967948 0.80 PTGS2 (0.44) ADRA2BPTGS2PTGS1CXCL8AKR1C3
SCHEMBL1261293 0.79 PTGS2 (0.46) ADRA2BPTGS2PTGS1CXCL8AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1666472-B1 PHENYLACETIC ACID DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE ONO PHARMACEUTICAL CO (JP) 2012-08-01 EP disclosed
US-7560475-B2 Phenylacetic acid derivative, process for producing the same, and use ONO PHARMACEUTICAL CO., LTD. (JP) 2009-07-14 US disclosed
US-20070105868-A1 Phenylacetic acid derivative, process for producing the same, and use ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-10 US disclosed
EP-1666472-A1 PHENYLACETIC ACID DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE ONO PHARMACEUTICAL CO., LTD. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105868-A1 Phenylacetic acid derivative, process for producing the same, and use PPARA, PPARD, PPARG ADRA2B 31/4885ADRB1 7/4885ADRA2A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.